UROGEN PHARMA LTD
UroGen Pharma Ltd (URGN) is a speciality biopharmaceutical company focused on urology and uro-oncology. The business develops treatments using a local drug‑delivery platform designed to retain therapeutic agents in the urinary tract, and it commercialises products for rare or difficult-to-treat urological cancers. With a market capitalisation around $839m, UroGen sits in the small‑to‑mid cap biotech space where clinical progress, regulatory decisions and early commercial traction drive value. Investors should note the typical biotech profile: potential for significant upside if clinical and commercial milestones are met, but also meaningful risks including trial setbacks, regulatory uncertainty, reimbursement challenges and share dilution from future fundraising. Performance can be volatile and past performance is not a reliable indicator of future results. This summary is educational and not personal financial advice; suitability depends on your circumstances and you should consult a financial professional before investing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Urogen Pharma's stock with a target price of $35.25, indicating strong potential growth.
Financial Health
UROGEN Pharma is successfully generating high profits and cash flow, indicating strong financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring URGN
New Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Commercial momentum
JELMYTO and other commercial activities can drive revenue growth if adoption and reimbursement progress; revenue can be uneven and is subject to payer decisions.
Platform potential
The local delivery platform aims to improve drug retention in the urinary tract, which may offer clinical advantages; clinical validation and uptake remain key uncertainties.
Regulatory pathway
Approvals, label expansions and international reimbursement shape long-term prospects, though regulatory and market hurdles can create volatility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.